Acamprosate
Acamprosate, sold under the brand name Campral, is a medication used along with counseling to treat alcohol use disorder.
Clinical data | |
---|---|
Pronunciation | /əˈkæmproʊseɪt/ |
Trade names | Campral EC |
Other names | N-Acetyl homotaurine, Acamprosate calcium (JAN JP), Acamprosate calcium (USAN US) |
Pregnancy category |
|
Routes of administration | Oral |
ATC code | |
Legal status | |
Legal status | |
Pharmacokinetic data | |
Bioavailability | 11% |
Protein binding | Negligible |
Metabolism | Nil |
Elimination half-life | 20 h to 33 h |
Excretion | Kidney |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
IUPHAR/BPS | |
DrugBank | |
ChemSpider | |
UNII | |
KEGG | |
ChEBI | |
ChEMBL | |
CompTox Dashboard (EPA) | |
ECHA InfoCard | 100.071.495 |
Chemical and physical data | |
Formula | C5H11NO4S |
Molar mass | 181.21 g·mol−1 |
3D model (JSmol) | |
| |
| |
(what is this?) (verify) |
Acamprosate is thought to stabilize chemical signaling in the brain that would otherwise be disrupted by alcohol withdrawal. When used alone, acamprosate is not an effective therapy for alcohol use disorder in most individuals; studies have found that acamprosate works best when used in combination with psychosocial support since the drug facilitates a reduction in alcohol consumption as well as full abstinence.
Serious side effects include allergic reactions, abnormal heart rhythms, and low or high blood pressure, while less serious side effects include headaches, insomnia, and impotence. Diarrhea is the most common side-effect. It is unclear if use is safe during pregnancy.
It is on the World Health Organization's List of Essential Medicines.